PublisherDOIYearVolumeIssuePageTitleAuthor(s)Link
Clinical Oncology10.1016/j.clon.2017.01.0272017296e101The 21-gene Recurrence Score: Impact on Adjuvant Chemotherapy Decisions in Early Breast Cancer, West of Scotland Cancer Centre ExperienceA. Morton, I. MacPherson, H. Marashihttps://api.elsevier.com/content/article/PII:S0936655517300535?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0936655517300535?httpAccept=text/plain
SpringerPlus10.1186/2193-1801-3-71201431Treatment decisions in estrogen receptor-positive early breast cancer patients with intermediate oncotype DX recurrence score resultsGeorgeta Fried, Mor Moskovitzhttp://link.springer.com/content/pdf/10.1186/2193-1801-3-71.pdf, http://link.springer.com/article/10.1186/2193-1801-3-71/fulltext.html, http://link.springer.com/content/pdf/10.1186/2193-1801-3-71.pdf
npj Breast Cancer10.1038/s41523-021-00231-x202171Lymphovascular invasion, race, and the 21-gene recurrence score in early estrogen receptor-positive breast cancerDella Makower, Juan Lin, Xiaonan Xue, Joseph A. Sparanohttp://www.nature.com/articles/s41523-021-00231-x.pdf, http://www.nature.com/articles/s41523-021-00231-x, http://www.nature.com/articles/s41523-021-00231-x.pdf
The Breast10.1016/s0960-9776(11)70141-2201120S44P200 Impact of the 21-gene recurrence score assay on treatment decision in early breast cancer (EBC) patients with favourable prognostic factorsC. Markopouloshttps://api.elsevier.com/content/article/PII:S0960977611701412?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0960977611701412?httpAccept=text/plain
The Breast10.1016/s0960-9776(17)30281-3201732S87Poor concordance between 21-gene expression assay recurrence score and all Magee equation recurrence scores in a consecutive cohort of patients treated for hormone receptor positive early breast cancerZ. Abdel-Rahman, H. Ali, L. Favazza, D. Chitalehttps://api.elsevier.com/content/article/PII:S0960977617302813?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0960977617302813?httpAccept=text/plain
npj Breast Cancer10.1038/s41523-018-0082-6201841Clinical relevance of the 21-gene Recurrence ScoreĀ® assay in treatment decisions for patients with node-positive breast cancer in the genomic eraEleftherios P. Mamounas, Christy A. Russell, Anna Lau, Michelle P. Turner, Kathy S. Albainhttp://www.nature.com/articles/s41523-018-0082-6.pdf, http://www.nature.com/articles/s41523-018-0082-6, http://www.nature.com/articles/s41523-018-0082-6.pdf
Breast Cancer Research and Treatment10.1007/s10549-013-2603-12013140183-92The impact of the 21-gene Recurrence Score assay on clinical decision-making in node-positive (up to 3 positive nodes) estrogen receptor-positive breast cancer patientsSalomon M. Stemmer, Shmuel H. Klang, Noa Ben-Baruch, David B. Geffen, Mariana Steiner, Lior Soussan-Gutman, Shahar Merling, Christer Svedman, Shulamith Rizel, Nicky Liebermanhttp://link.springer.com/content/pdf/10.1007/s10549-013-2603-1.pdf, http://link.springer.com/article/10.1007/s10549-013-2603-1/fulltext.html, http://link.springer.com/content/pdf/10.1007/s10549-013-2603-1
Breast Cancer Research and Treatment10.1007/s10549-021-06228-12021Prognostic value of the 21-gene recurrence score for regional recurrence in patients with estrogen receptor-positive breast cancerMinji Koh, Jinhong Jung, Su Ssan Kim, Seung Do Ahn, Eun Kyung Choi, Il Yong Chung, Jong Won Lee, Sung-Bae Kim, Jae Ho Jeonghttps://link.springer.com/content/pdf/10.1007/s10549-021-06228-1.pdf, https://link.springer.com/article/10.1007/s10549-021-06228-1/fulltext.html, https://link.springer.com/content/pdf/10.1007/s10549-021-06228-1.pdf
Breast Cancer Research and Treatment10.1007/s10549-017-4162-320171632303-310Breast cancer-specific survival in patients with lymph node-positive hormone receptor-positive invasive breast cancer and Oncotype DX Recurrence Score results in the SEER databaseMegan C. Roberts, Dave P. Miller, Steven Shak, Valentina I. Petkovhttp://link.springer.com/content/pdf/10.1007/s10549-017-4162-3.pdf, http://link.springer.com/article/10.1007/s10549-017-4162-3/fulltext.html, http://link.springer.com/content/pdf/10.1007/s10549-017-4162-3.pdf
Journal of the Egyptian National Cancer Institute10.1186/s43046-020-00025-52020321Implications of the 21-gene recurrence score assay (Oncotype DX) on adjuvant treatment decisions in ER-positive early-stage breast cancer patients: experience of Kuwait Cancer Control CenterSalah Fayaz, Heba El-Sayed Eissa, Gerges Attia Demianhttp://link.springer.com/content/pdf/10.1186/s43046-020-00025-5.pdf, http://link.springer.com/article/10.1186/s43046-020-00025-5/fulltext.html, http://link.springer.com/content/pdf/10.1186/s43046-020-00025-5.pdf